EVALUATION OF THE THERAPEUTIC EFFICACY OF PRECONDITIONED MESENCHYMAL STEM CELLS IN A MOUSE MODEL OF PSORIASIS: PASI AND HISTOLOGICAL ANALYSIS
Main Article Content
Authors
A.K. Dairov
Stem Cell Laboratory, National Center for Biotechnology, Astana, Kazakhstan
A.S. Issabekova
Stem Cell Laboratory, National Center for Biotechnology, Astana, Kazakhstan
V.B. Ogay
Stem Cell Laboratory, National Center for Biotechnology, Astana, Kazakhstan
Abstract
Psoriasis is a common immune-mediated inflammatory skin disease that affects 2-4% of the world's population and about 2.5% of the population of Kazakhstan. Mesenchymal stem cells (MSCs) are of particular interest for the treatment of psoriasis due to their strong immunomodulatory and regenerative potential. One of the strategies to increase the therapeutic efficacy of MSCs is their preconditioning with proinflammatory cytokines, which improves their survival and immunoregulatory properties. Aim of the study: Evaluation of the therapeutic effect of human umbilical cord blood mesenchymal stem cells (hUCB-MSCs) preconditioned with combinations of the cytokines interleukin (IL)-17A, IL-22, and tumor necrosis factor-alpha (TNF-α) in a mouse model of imiquimod (IMQ)-induced psoriasis-like skin inflammation. Results: Assessment of skin inflammation severity using the PASI score, along with subsequent histological analysis, demonstrated that both intact and preconditioned hUCB-MSCs effectively reduced IMQ-induced skin inflammation. In addition, hUCB-MSCs preconditioned with a combination of IL-22 and TNF-α significantly reduced erythema and scaling, while hUCB-MSCs preconditioned with a combination of IL-17A, IL-22 and TNF-α significantly reduced skin thickening. Conclusion: Preconditioned hUCB-MSCs exhibit a pronounced anti-inflammatory potential, confirming their therapeutic promise for the treatment of psoriasis.
Keywords
human umbilical cord blood-derived mesenchymal stem cells, preconditioning, pro-inflammatory cytokines, psoriasis, PASI (Psoriasis Area and Severity Index), histology
Article Details
References
Branisteanu D.E., Cojocaru C., Diaconu R., Porumb E.A., Alexa A.I., Nicolescu A.C., Brihan I., Bogdanici C.M., Branisteanu G., Dimitriu A., Zemba M., Anton N., Toader M.P., Grechin A., Branisteanu D.C. Update on the etiopathogenesis of psoriasis (review) // Experimental and Therapeutic Medicine. – 2022. – Vol. 23, No. 3. – Art. 201. PMID: 35126704 doi: 10.3892/etm.2022.11124
Dairov A., Issabekova A., Sekenova A., Shakhatbayev M., Ogay V. Prevalence, incidence, gender and age distribution, and economic burden of psoriasis worldwide and in Kazakhstan // Journal of Clinical Medicine of Kazakhstan. – 2024. – Vol. 21, No. 2. – P. 18-30. doi: 10.23950/jcmk/14497
Agarwal K., Das A., Das S., De A. Impact of psoriasis on quality of life // Indian Journal of Dermatology. – 2022. – Vol. 67, No. 4. – P. 387-391. PMID: 36578706 doi: 10.4103/ijd.ijd_572_22
Dairov A., Sekenova A., Alimbek S., Nurkina A., Shakhatbayev M., Kumasheva V., Kuanysh S., Adish Zh., Issabekova A., Ogay V. Psoriasis: The versatility of mesenchymal stem cell and exosome therapies // Biomolecules. – 2024. – Vol. 14, No. 11. – Art. 1351. PMID: 39595528 doi: 10.3390/biom14111351
Saeedi P., Halabian R., Fooladi A.A.I. A revealing review of mesenchymal stem cells therapy, clinical perspectives and modification strategies // Stem Cell Investigation. – 2019. – Vol. 6. – Art. 34. PMID: 31620481 doi: 10.21037/sci.2019.08.11
Hmadcha A., Martin-Montalvo A., Gauthier B.R., Soria B., Capilla-Gonzalez V. Therapeutic potential of mesenchymal stem cells for cancer therapy // Frontiers in Bioengineering and Biotechnology. – 2020. – Vol. 8. – Art. 43. PMID: 32117924 doi: 10.3389/fbioe.2020.00043
Griffiths C.E.M., Armstrong A.W., Gudjonsson J.E., Barker J.N.W.N. Psoriasis // Lancet. – 2021. – Vol. 397, No. 10281. – P. 1301-1315. PMID: 33812489 doi: 10.1016/s0140-6736(20)32549-6
Zhao J., Di T., Wang Y., Liu X., Liang D., Zhang G., Li P. Multi-glycoside of Tripterygium wilfordii Hook. f. ameliorates imiquimod-induced skin lesions through a STAT3-dependent mechanism involving the inhibition of Th17-mediated inflammatory responses // International Journal of Molecular Medicine. – 2016. – Vol. 38, No. 3. – P. 747-757. PMID: 27431437 doi: 10.3892/ijmm.2016.2670
Zhang P., Su Y., Li S., Chen H., Wu R., Wu H. The roles of T cells in psoriasis // Frontiers in Immunology. – 2023. – Vol. 14. – Art. 1081256. PMID: 37942312 doi: 10.3389/fimmu.2023.1081256
Saparov A., Ogay V., Nurgozhin T., Jumabay M., Chen W.C.W. Preconditioning of human mesenchymal stem cells to enhance their regulation of the immune response // Stem Cells International. – 2016. – Vol. 2016. – Art. 3924858. PMID: 27822228 doi: 10.1155/2016/3924858
Baliwag J., Barnes D.H., Johnston A. Cytokines in psoriasis // Cytokine. – 2015. – Vol. 73, No. 2. – P. 342-350. PMID: 25585875 doi: 10.1016/j.cyto.2014.12.014
van der Fits L., Mourits S., Voerman J.S.A., Kant M., Boon L., Laman J.D., Cornelissen F., Mus A.-M., Florencia E., Prens E.P., Lubberts E. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis // The Journal of Immunology. – 2009. – Vol. 182, No. 9. – P. 5836-5845. PMID: 19380832 doi: 10.4049/jimmunol.0802999
Baker B.S., Brent L., Valdimarsson H., Powles A.V., al-Imara L., Walker M., Fry L. Is epidermal cell proliferation in psoriatic skin grafts on nude mice driven by T-cell derived cytokines? // British Journal of Dermatology. – 1992. – Vol. 126, No. 2. – P. 105-110. PMID: 1536776 doi: 10.1111/j.1365-2133.1992.tb07805.x
De Rosa G., Mignogna C. The histopathology of psoriasis // Reumatismo. – 2007. – Vol. 59, Suppl 1. – P. 46-48. PMID: 17828343 doi: 10.4081/reumatismo.2007.1s.46
Pittenger M.F., Discher D.E., Péault B.M., Phinney D.G., Hare J.M., Caplan A.I. Mesenchymal stem cell perspective: cell biology to clinical progress // NPJ Regenerative Medicine. – 2019. – Vol. 4. – Art. 22. PMID: 31815001 doi: 10.1038/s41536-019-0083-6
Zaripova L.N., Midgley A., Christmas S.E., Beresford M.W., Pain C., Baildam E.M., Oldershaw R.A. Mesenchymal stem cells in the pathogenesis and therapy of autoimmune and autoinflammatory diseases // International Journal of Molecular Sciences. – 2023. – Vol. 24, No. 22. – Art. 16040. PMID: 38003230 doi: 10.3390/ijms242216040
Ding D.-C., Shyu W.-C., Lin S.-Z. Mesenchymal stem cells // Cell Transplantation. – 2011. – Vol. 20, No. 1. – P. 5-14. PMID: 21396235 doi: 10.3727/096368910x
Jasim S.A., Yumashev A.V., Abdelbasset W.K., Margiana R., Markov A., Suksatan W., Pineda B., Thangavelu L., Ahmadi S.H. Shining the light on clinical application of mesenchymal stem cell therapy in autoimmune diseases // Stem Cell Research and Therapy. – 2022. – Vol. 13, No. 1. – Art. 101. PMID: 35255979 doi: 10.1186/s13287-022-02782-7
Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses // Blood. – 2005. – Vol. 105, No. 4. – P. 1815-1822. PMID: 15494428 doi: 10.1182/blood-2004-04-1559
Ye Z., Liang Y., Lin B., Li Y., Chai X., Lian J., Zhang X., Che Z., Zeng J. Gingiva-derived mesenchymal stem cells attenuate imiquimod- (IMQ-) induced murine psoriasis-like skin inflammation // Stem Cells International. – 2022. – Vol. 2022. – Art. 6544514. PMID: 35813890 doi: 10.1155/2022/6544514
Lee Y.S., Sah S.K., Lee J.H., Seo K.-W., Kang K.-S., Kim T.-Y. Human umbilical cord blood-derived mesenchymal stem cells ameliorate psoriasis-like skin inflammation in mice // Biochemistry and Biophysics Reports. – 2016. – Vol. 9. – P. 281-288. PMID: 28956015 doi: 10.1016/j.bbrep.2016.10.002
Ding Y., Gong P., Jiang J., Feng C., Li Y., Su X., Bai X., Xu C., Liu C., Yang J., Fang J., Ji X., Chen Y., Li P., Guo L., Shao C., Shi Y. Mesenchymal stem/stromal cells primed by inflammatory cytokines alleviate psoriasis-like inflammation via the TSG-6-neutrophil axis // Cell Death and Disease. – 2022. – Vol. 13, No. 11. – Art. 996. Crossref
Chen Y., Hu Y., Zhou X., Zhao Z., Yu Q., Chen Z., Wang Y., Xu P., Yu Z., Guo C., Zhang X., Shi Y. Human umbilical cord-derived mesenchymal stem cells ameliorate psoriasis-like dermatitis by suppressing IL-17-producing γδ T cells // Cell and Tissue Research. – 2022. – Vol. 388, No. 3. – P. 549-563. PMID: 35347409 doi: 10.1007/s00441-022-03616-x
Dashti M., Mohammadi M., Dehnavi S., Sadeghi M. Immunomodulatory interactions between mesenchymal stromal/stem cells and immune cells in psoriasis: therapeutic potential and challenges // Stem Cell Research and Therapy. – 2025. – Vol. 16, No. 1. – Art. 241. doi: 10.1186/s13287-025-04375-6
Hua C., Chen S., Cheng H. Therapeutic potential of mesenchymal stem cells for refractory inflammatory and immune skin diseases // Human Vaccines and Immunotherapeutics. – 2022. – Vol. 18, No. 6. – Art. 2144667. PMID: 36382475 doi: 10.1080/21645515.2022.2144667